CCO Oncology Podcast
Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
- Update frequency
- every 9 days
- Average duration
- 23 minutes
- Episodes
- 208
- Years Active
- 2020 - 2025
Multidisciplinary Overview of EGFR-Mutated NSCLC: An Expert Panel Discussion From Biomarker Testing to Managing Progressive Disease
In this podcast episode, Conor Ernst Steuer, MD, a medical oncologist; Frank Schneider, MD, a pathologist; and Elise Hitron, MSN, FNP-C, a phase I clinical trials nurse practitioner, engage in a mult…
Experts Answer Questions on Current and Emerging Options for Hemophilia A Management
In this podcast episode, 3 experts answers questions on the management of hemophilia A from a live webinar. Topics include:
|
Induction and Maintenance Therapy for Fit Patients With AML Without Targetable Mutations
In this podcast episode, Ashley Leak Bryant, PhD, RN, OCN, FAAN, discusses therapeutic options for younger, fit patients with AML and no targetable mutations. Topics include:
- Induction chemotherapy an…
Strategies for Secondary AML and Emerging Therapies for AML
In this podcast episode, Sarah M. Tinsley, PhD, APRN, AOCN, discusses management strategies for secondary AML and novel therapies currently in clinical trials for AML. Topics include:
- Liposomal cytara…
Targeted Treatment Options for Patients With AML and FLT3 or IDH1/2 Mutations
In this podcast episode, Sarah M. Tinsley, PhD, APRN, AOCN, discusses targeted therapy with FLT3 and IDH1/2 inhibitors in AML, with a focus on the nursing perspective. Topics include:
- Approved and eme…
An Overview of AML and Treatment Strategies for Patients Unfit for Intensive Therapy
In this podcast episode, Ashley Leak Bryant, PhD, RN, OCN, FAAN, discusses acute myeloid leukemia and management approaches for patients unfit for intensive chemotherapy, with a focus on the nursing …
Managing Lower-Risk Myelodysplastic Syndrome: Nursing Implications
In this podcast episode, Ashley Leak Bryant, PhD, RN, OCN, FAAN, discusses management strategies for lower-risk myelodysplastic syndrome (MDS) with a focus on the nursing perspective. Topics include
- …
Managing Higher-Risk and Relapsed/Refractory Myelodysplastic Syndromes: Nursing Implications
In this podcast episode,Sarah Tinsley, PhD, APRN, AOCN, discusses management strategies for higher-risk and relapsed/refractory (R/R) myelodysplastic syndromes (MDS) with a focus on the nursing pers…
Key Factors Influencing Later-Line Treatment Selection for Patients With Metastatic Colorectal Cancer
In this episode, Chiara Cremolini, MD, PhD, and Teresa Macarulla, MD, PhD, discuss the clinical data that inform how they select regorafenib and TAS-102 as later-line treatment for patients with mCRC…
The Evolving Role of TKIs in First-line Treatment of Advanced HCC
In this podcast episode from Clinical Care Options (CCO), Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss first-line treatment of patients with advanced hepatocellular carci…
Expert Insight on Important Clinical Trial Data From ESGO 2021 Informing Treatment for Ovarian Cancer and Endometrial Cancers
In this episode, Nicole Concin, MD, PhD, highlights key data for endometrial and ovarian cancers presented at the ESGO 2021 annual meeting, including:
- Pooled data from 7 phase III clinical trials eva…
Experts Answer FAQs on Immunotherapy for Non-Small-Cell Lung Cancer
In this podcast episode, Julie Brahmer, MD, MSc, and Jarushka Naidoo, MB BCH BAO, MHS, answer audience questions from a live CCO webinar on evolving immunotherapy strategies for NSCLC, with topics in…
Overcoming Acquired Resistance With Second-Generation TRK Inhibitors
In this podcast episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss emerging data on the efficacy, safety, and clinical role of second-generation TRK inhibitors that can overcome acquir…
Role of TKIs in Nonadipocytic Soft Tissue Sarcoma and Advanced Osteosarcoma
In this podcast episode, Jean-Yves Blay, MD, PhD, and Robin L. Jones, BSc, MBBS, MRCP, MD(Res), discuss the most important clinical trial data on leveraging TKIs as monotherapy and in combination wit…
PARP Inhibitors in Pancreatic Cancer: Experts Discuss Importance of Testing for Biomarkers Along With Current Treatment Landscape
In this episode, Philip Agop Philip, MD, PhD, FRCP, and Elena Gabriela Chiorean, MD, discuss the importance of testing for biomarkers along with thecurrent paradigm of PARP inhibitor therapy in the t…
Optimal Dosing Strategies With Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer
In this episode, Kanwal Raghav, MD, and Rachel Riechelmann, MD, PhD, discuss key data supporting contemporary dosing strategies with the later-line treatment options regorafenib and TAS-102 for patie…
First-Generation TRK Inhibitors: Clinical Evidence and Indications
In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss key clinical data leading to FDA approvals and current indications for first-generation TRK inhibitors in NTRK fusion–positiv…
PARP Inhibitors in Ovarian Cancer: Experts Discuss Patient Cases and the Current Paradigm
In this episode, Nicoletta Colombo, MD; Philipp Harter, MD, PhD; and Alexandra Leary, MD, PhD, discuss patient cases from a live webinar on the current paradigm and long-term benefits of PARPi thera…
Counseling Patients and Caregivers on Prophylaxis Therapy for Severe Hemophilia A
In this episode, listen to Guy A. Young, MD, as he counsels a teenage patient with severe hemophilia A and the patient’s mother on various available treatment options and strategies for optimizing he…
Rationale for NTRK Testing in Patients With Cancer
In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss the biologic rationale behind testing for NTRK fusions in patients with various solid tumors, along with clinical strategies …